Low Dose Naltrexone (LDN): Immune Modulation & Integrative Applications

This article is provided for educational purposes only. It documents how integrative medical doctors, researchers, and holistic practitioners approach Low Dose Naltrexone based on published research and clinical experience. This is not medical advice. LDN requires a valid prescription from a licensed healthcare provider. Always consult a qualified healthcare professional before beginning any treatment protocol.

What Is Low Dose Naltrexone?

Naltrexone is an opioid antagonist originally approved by the FDA in 1984 at doses of 50mg for the treatment of opioid and alcohol dependence. At this standard dose, it works by blocking opioid receptors continuously, preventing the euphoric effects of opioids.

Low Dose Naltrexone (LDN) refers to the use of naltrexone at a fraction of the standard dose — typically in the range of 1.5mg to 4.5mg — taken once daily, usually at bedtime. At this dramatically reduced dose, the mechanism of action shifts entirely. Rather than blocking opioid receptors continuously, LDN produces a brief, transient blockade that triggers a powerful rebound upregulation of the body’s own endogenous opioid system — with profound downstream effects on immune function, inflammation, and cellular health.

The Science: How LDN Works

The Endorphin Rebound Mechanism

When LDN is taken at bedtime, it transiently blocks opioid receptors for approximately 4–6 hours during the early morning hours — a period when the body naturally produces its highest levels of endogenous opioids (endorphins and enkephalins). The brain, sensing this transient blockade, responds by dramatically upregulating the production of endogenous opioids and increasing the sensitivity and number of opioid receptors.

This rebound effect results in significantly elevated endorphin levels during the remaining 18–20 hours of the day when LDN is no longer blocking receptors. Since endorphins play a critical role in immune regulation, this sustained elevation has wide-ranging effects on immune function.

A foundational body of research by Dr. Ian Zagon, PhD and Dr. Patricia McLaughlin, PhD at Penn State University College of Medicine, published across Brain Research, Experimental Biology and Medicine, and Cancer Letters, established the role of the opioid growth factor (OGF) — met-enkephalin — and its receptor (OGFr) in regulating cell proliferation. Their work demonstrated that LDN’s transient blockade of OGFr leads to a compensatory upregulation of OGF-OGFr signaling — which exerts a direct inhibitory effect on abnormal cell growth.

Microglial Modulation — The Neuroinflammation Connection

LDN also acts on Toll-like receptor 4 (TLR4) on microglial cells — the immune cells of the central nervous system. At low doses, naltrexone functions as a TLR4 antagonist, inhibiting microglial activation and the downstream production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-12.

Dr. Jill Smith, MD, a gastroenterologist at Penn State Hershey Medical Center, published a landmark pilot study in The American Journal of Gastroenterology (Smith et al., 2011) demonstrating that LDN significantly reduced disease activity in patients with Crohn’s disease. A subsequent randomized controlled trial confirmed these findings, with 88% of LDN-treated patients showing a significant response compared to 40% in the placebo group.

Dr. Bernard Bihari — The Pioneer of LDN

Dr. Bernard Bihari, MD (1931–2010) was a Harvard-trained neurologist practicing in New York City who is widely credited as the father of LDN therapy. In the mid-1980s, while treating patients with AIDS, Dr. Bihari observed that many of his patients had severely depressed endorphin levels. He hypothesized that boosting endogenous opioid production through transient receptor blockade might restore immune function.

Beginning in 1985, Dr. Bihari began administering low doses of naltrexone to his AIDS patients and documented remarkable stabilization of immune function — with CD4 counts holding steady in patients who would otherwise have been expected to decline rapidly. He subsequently expanded his clinical use of LDN to cancer patients, observing tumor stabilization and regression across multiple cancer types including non-Hodgkin’s lymphoma, pancreatic cancer, colon cancer, and breast cancer.

In his own words, Dr. Bihari described LDN as “one of the most remarkable and underutilized tools in medicine — a safe, inexpensive intervention that appears to restore the immune system’s ability to do what it was designed to do.”

LDN in Cancer — What the Research Shows

The primary mechanisms proposed for LDN’s anticancer activity include OGF-OGFr-mediated inhibition of tumor cell proliferation, immune upregulation via endorphin rebound, and anti-angiogenic effects that may limit tumor blood supply.

Pancreatic Cancer: A case report published in Integrative Cancer Therapies (Berkson et al., 2006) documented the stabilization of advanced pancreatic cancer in a patient treated with alpha-lipoic acid and LDN — the “Berkson Protocol” developed by Dr. Burton Berkson, MD, PhD. The patient, given weeks to live, survived for years with stable disease. Dr. Berkson subsequently published additional case series documenting similar responses.

Ovarian Cancer: Research by Dr. Zagon and Dr. McLaughlin published in Gynecologic Oncology demonstrated that OGF significantly inhibited the growth of human ovarian cancer cells in vitro and in animal models, reducing tumor volume by up to 65% compared to controls.

Glioblastoma: A study published in Frontiers in Oncology (Donahue et al., 2011) documented LDN’s inhibitory effects on glioblastoma cell lines, with OGF-OGFr signaling shown to suppress tumor cell DNA synthesis.

Breast Cancer: Research published in Cancer Letters (Berkson et al., 2010) documented OGF’s inhibitory effects on human breast cancer cell lines, with the authors concluding that “the OGF-OGFr axis represents a novel target for breast cancer therapy.”

LDN in Autoimmune Disease

Multiple Sclerosis: A randomized, double-blind, placebo-controlled trial published in Multiple Sclerosis Journal (Cree et al., 2010) found that LDN significantly improved mental health quality of life scores in MS patients. Dr. David Younger, MD, a neurologist and MS specialist, has written extensively on LDN’s neuroprotective potential via microglial inhibition.

Fibromyalgia: A pilot study published in Pain Medicine (Younger & Mackey, 2009) by Dr. Jarred Younger, PhD at Stanford University found that LDN reduced fibromyalgia pain scores by 30% compared to placebo, attributed to microglial inhibition and reduction of central sensitization. A subsequent larger trial confirmed these findings.

Crohn’s Disease: Dr. Jill Smith’s RCT demonstrated significant clinical response with mucosal healing documented on endoscopy — a striking finding given LDN’s minimal side effect profile compared to standard immunosuppressive therapies.

Practitioner Perspectives

Dr. Thomas Cowan, MD, author of Cancer and the New Biology of Water, describes LDN as “one of the few interventions I’ve seen that appears to genuinely restore immune intelligence rather than simply suppressing or stimulating one arm of the immune system.”

Dr. Paul Anderson, NMD, naturopathic oncologist and co-author of Outside the Box Cancer Therapies, describes LDN as “a foundational agent in our integrative oncology toolkit — safe, well-tolerated, and with a mechanism that complements virtually every other intervention we use.”

Dr. Nasha Winters, ND, FABNO, author of The Metabolic Approach to Cancer, highlights LDN as a key component of metabolic cancer protocols, noting its synergy with ketogenic dietary interventions and its ability to support immune surveillance without the toxicity of conventional immunosuppressants.

The LDN Research Trust, a UK-based nonprofit founded by Linda Elsegood, has compiled one of the largest patient outcome databases for LDN globally, documenting responses across over 100 conditions. Over 40 clinical trials are currently registered on ClinicalTrials.gov investigating LDN across conditions ranging from cancer and MS to long COVID and Parkinson’s disease.

Safety Profile

LDN has an exceptionally favorable safety profile. The most commonly reported side effect is vivid dreams or mild sleep disturbance during the initial weeks of use, attributed to the transient opioid blockade occurring during sleep — this typically resolves within 2–4 weeks. LDN does not suppress the immune system, does not cause organ toxicity at low doses, and does not interact with most medications. The primary contraindication is concurrent use of opioid medications.

This article is for educational purposes only. Consult a qualified healthcare provider before starting any new supplement or treatment protocol. LDN requires a valid prescription from a licensed healthcare provider.